Krista L Lanctot

Summary

Affiliation: Sunnybrook and Women's College Health Sciences Centre
Country: Canada

Publications

  1. ncbi request reprint GABAergic function in Alzheimer's disease: evidence for dysfunction and potential as a therapeutic target for the treatment of behavioural and psychological symptoms of dementia
    Krista L Lanctot
    Department of Psychiatry, Sunnybrook and Women s College Health Sciences Centre, University of Toronto, Ontario
    Can J Psychiatry 49:439-53. 2004
  2. ncbi request reprint Medial temporal hypoperfusion and aggression in Alzheimer disease
    Krista L Lanctot
    Neuropharmacology Research, Department of Psychiatry, Cognitive Neurology Unit, Sunnybrook and Women s College Health Sciences Centre, University of Toronto, Ontario, Canada
    Arch Neurol 61:1731-7. 2004
  3. pmc Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis
    Krista L Lanctot
    Neuropharmacology Research Program, Department of Psychiatry, Sunnybrook and Women s College Health Sciences Centre, Toronto, ON
    CMAJ 169:557-64. 2003
  4. ncbi request reprint The cost-benefit of cholinesterase inhibitors in mild to moderate dementia: a willingness-to-pay approach
    Grace Wu
    Department of Psychiatry, HOPE Research Centre and Division of Clinical Pharmacology, Room FG 05, Sunnybrook and Women s College Health Sciences Centre, University of Toronto, 2075 Bayview Avenue, Toronto, Ontario M4N 3M5, Canada
    CNS Drugs 17:1045-57. 2003
  5. pmc Genetic predictors of response to treatment with citalopram in depression secondary to traumatic brain injury
    Krista L Lanctot
    Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
    Brain Inj 24:959-69. 2010
  6. doi request reprint The effect of cholinesterase inhibitors on decline in multiple functional domains in Alzheimer's disease: a two-year observational study in the Sunnybrook dementia cohort
    Pearl Behl
    Linda C Campbell Cognitive Neurology Research Unit, University of Toronto, Canada
    Int Psychogeriatr 20:1141-59. 2008
  7. ncbi request reprint The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease
    Sarah Thompson
    Sunnybrook and Women s College Health Sciences Centre, Department of Psychiatry, Rm FG 05, 2075 Bayview Avenue, Toronto, ON, M4N 3M5, Canada
    Expert Opin Drug Saf 3:425-40. 2004
  8. doi request reprint Comparison of the cost of hospitalization for respiratory syncytial virus disease versus palivizumab prophylaxis in Canadian Inuit infants
    Anna Banerji
    Department of Pediatrics and Dalla Lana School of Public Health, St Michael s Hospital, University of Toronto, Toronto, Canada
    Pediatr Infect Dis J 28:702-6. 2009
  9. ncbi request reprint The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis
    Krista L Lanctot
    Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
    Curr Med Res Opin 24:3223-37. 2008
  10. pmc The relationship between indoleamine 2,3-dioxygenase activity and post-stroke cognitive impairment
    Allison B Gold
    Neuropsychopharmacology Research Group, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
    J Neuroinflammation 8:17. 2011

Collaborators

Detail Information

Publications75

  1. ncbi request reprint GABAergic function in Alzheimer's disease: evidence for dysfunction and potential as a therapeutic target for the treatment of behavioural and psychological symptoms of dementia
    Krista L Lanctot
    Department of Psychiatry, Sunnybrook and Women s College Health Sciences Centre, University of Toronto, Ontario
    Can J Psychiatry 49:439-53. 2004
    ..We review the clinical use of GABAergic agents in treating persons with AD symptoms. While newer generation GABAergic medications are now available, they have yet to be evaluated among patients with AD...
  2. ncbi request reprint Medial temporal hypoperfusion and aggression in Alzheimer disease
    Krista L Lanctot
    Neuropharmacology Research, Department of Psychiatry, Cognitive Neurology Unit, Sunnybrook and Women s College Health Sciences Centre, University of Toronto, Ontario, Canada
    Arch Neurol 61:1731-7. 2004
    ..It is not understood why some patients with Alzheimer disease (AD) display aggression and others do not...
  3. pmc Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis
    Krista L Lanctot
    Neuropharmacology Research Program, Department of Psychiatry, Sunnybrook and Women s College Health Sciences Centre, Toronto, ON
    CMAJ 169:557-64. 2003
    ..Our objective was to quantitatively summarize data on the efficacy and safety of ChEIs in Alzheimer's disease in a format useful to clinicians...
  4. ncbi request reprint The cost-benefit of cholinesterase inhibitors in mild to moderate dementia: a willingness-to-pay approach
    Grace Wu
    Department of Psychiatry, HOPE Research Centre and Division of Clinical Pharmacology, Room FG 05, Sunnybrook and Women s College Health Sciences Centre, University of Toronto, 2075 Bayview Avenue, Toronto, Ontario M4N 3M5, Canada
    CNS Drugs 17:1045-57. 2003
    ..This study aimed to measure the economic value of cholinesterase inhibitors when used to treat Alzheimer's disease using the willingness-to-pay (WTP) approach and the framework of cost-benefit analysis...
  5. pmc Genetic predictors of response to treatment with citalopram in depression secondary to traumatic brain injury
    Krista L Lanctot
    Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
    Brain Inj 24:959-69. 2010
    ..To determine which serotonergic system-related single nucleotide polymorphisms (SNPs) predicted variation in treatment response to citalopram in depression following a traumatic brain injury (TBI)...
  6. doi request reprint The effect of cholinesterase inhibitors on decline in multiple functional domains in Alzheimer's disease: a two-year observational study in the Sunnybrook dementia cohort
    Pearl Behl
    Linda C Campbell Cognitive Neurology Research Unit, University of Toronto, Canada
    Int Psychogeriatr 20:1141-59. 2008
    ..This study seeks to assess change in activities of daily living (ADLs) over two years in AD patients treated with CHEIs matched to untreated patients in the same longitudinal cohort study...
  7. ncbi request reprint The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease
    Sarah Thompson
    Sunnybrook and Women s College Health Sciences Centre, Department of Psychiatry, Rm FG 05, 2075 Bayview Avenue, Toronto, ON, M4N 3M5, Canada
    Expert Opin Drug Saf 3:425-40. 2004
    ..Further study is needed to examine other indications for ChEIs, as well as their combination with newer treatments, such as memantine...
  8. doi request reprint Comparison of the cost of hospitalization for respiratory syncytial virus disease versus palivizumab prophylaxis in Canadian Inuit infants
    Anna Banerji
    Department of Pediatrics and Dalla Lana School of Public Health, St Michael s Hospital, University of Toronto, Toronto, Canada
    Pediatr Infect Dis J 28:702-6. 2009
    ....
  9. ncbi request reprint The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis
    Krista L Lanctot
    Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
    Curr Med Res Opin 24:3223-37. 2008
    ..The cost-effectiveness of this therapy in Canada is unknown...
  10. pmc The relationship between indoleamine 2,3-dioxygenase activity and post-stroke cognitive impairment
    Allison B Gold
    Neuropsychopharmacology Research Group, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
    J Neuroinflammation 8:17. 2011
    ....
  11. doi request reprint A randomized controlled trial of antidepressant continuation for major depression following traumatic brain injury
    Mark J Rapoport
    Sunnybrook Health Sciences Center, University of Toronto, Ontario, Canada
    J Clin Psychiatry 71:1125-30. 2010
    ..This study examines whether continuation therapy with citalopram can prevent a relapse following remission of major depression due to traumatic brain injury...
  12. doi request reprint A functional neuroimaging study of appetite loss in Alzheimer's disease
    Zahinoor Ismail
    Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
    J Neurol Sci 271:97-103. 2008
    ..Alzheimer's Disease (AD) is frequently associated with changes in appetite. This study investigated the relationship between regional cerebral perfusion and appetite loss in AD...
  13. doi request reprint Serotonergic function and treatment of behavioral and psychological symptoms of frontotemporal dementia
    Nathan Herrmann
    Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
    Am J Geriatr Psychiatry 20:789-97. 2012
    ....
  14. doi request reprint Are vascular risk factors associated with post-stroke depressive symptoms?
    Gayla Tennen
    Department of Clinical Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
    J Geriatr Psychiatry Neurol 24:215-21. 2011
    ..The objective of the current study was to determine whether VRFs are associated with the risk of PSD in an acute stroke population...
  15. doi request reprint Verbal memory performance and completion of cardiac rehabilitation in patients with coronary artery disease
    Walter Swardfager
    Neuropsychopharmacology Research Group, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
    Psychosom Med 73:580-7. 2011
    ..To assess cognitive performance as a predictor of noncompletion of cardiac rehabilitation (CR) using a standardized verbal memory test...
  16. doi request reprint The relationship between inflammatory markers and post stroke cognitive impairment
    Lana S Rothenburg
    Neuropsychopharmacology Research Group, Toronto, Ontario, Canada
    J Geriatr Psychiatry Neurol 23:199-205. 2010
    ..Enzyme-linked immunosorbent assay (ELISA) was used to measure serum concentrations of CRP, interleukin 6 (IL-6), and interferon gamma (IFN-gamma)...
  17. ncbi request reprint Noradrenergic activity is associated with response to pindolol in aggressive Alzheimer's disease patients
    Nathan Herrmann
    Department of Psychiatry, Sunnybrook and Women s College Health Sciences Centre and University of Toronto, Toronto, Ontario, Canada
    J Psychopharmacol 18:215-20. 2004
    ..Individual patient characteristics, including underlying neurotransmitter changes, may be useful for predicting response to therapy...
  18. doi request reprint Validity and responsiveness to change of clinically derived MDS scales in Alzheimer disease outcomes research
    Kelly A Smart
    Neuropsychopharmacology Research Program, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
    J Geriatr Psychiatry Neurol 24:67-72. 2011
    ..As these findings are preliminary, further research is needed to determine the utility of MDS scales in outcomes research...
  19. doi request reprint Cardiopulmonary fitness is associated with cognitive performance in patients with coronary artery disease
    Walter Swardfager
    Neuropsychopharmacology Research Group, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
    J Am Geriatr Soc 58:1519-25. 2010
    ..To investigate the association between cardiopulmonary fitness and cognitive performance in subjects with coronary artery disease (CAD)...
  20. ncbi request reprint Perceptions of natural health products among patients attending a memory clinic
    Papita Sharma
    Sunnybrook Health Sciences Centre, University of Toronto, Ontario, Canada
    Am J Alzheimers Dis Other Demen 21:156-63. 2006
    ..826, P = .005). Careful questioning during visits with health care providers and better counseling may be necessary to reduce the potential for adverse events and NHP-drug interactions...
  21. doi request reprint Apathy associated with Alzheimer disease: use of dextroamphetamine challenge
    Krista L Lanctot
    Department of Psychiatry, University of Toronto, Toronto, Canada
    Am J Geriatr Psychiatry 16:551-7. 2008
    ..To assess the role of the dopaminergic brain reward system (BRS) in apathy associated with Alzheimer disease (AD)...
  22. ncbi request reprint A placebo-controlled trial of valproate for agitation and aggression in Alzheimer's disease
    Nathan Herrmann
    Neuropharmacology Research Program, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
    Dement Geriatr Cogn Disord 23:116-9. 2007
    ..To assess the efficacy and tolerability of valproate for the treatment of agitation and aggression in moderate-to-severe Alzheimer's disease (AD)...
  23. doi request reprint Methylphenidate for the treatment of apathy in Alzheimer disease: prediction of response using dextroamphetamine challenge
    Nathan Herrmann
    Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
    J Clin Psychopharmacol 28:296-301. 2008
    ..Psychostimulants may be effective in treating features of apathy in AD, and dopaminergic changes may predict response...
  24. ncbi request reprint Serotonin-1A receptors in frontotemporal dementia compared with controls
    Krista L Lanctot
    Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
    Psychiatry Res 156:247-50. 2007
    ..These pilot data suggest that profound 5-HT(1A) BP losses may be present and contribute to symptomatology and treatment response in FTLD...
  25. doi request reprint Does pharmacological treatment of neuropsychiatric symptoms in Alzheimer's disease relieve caregiver burden?
    Karen Levy
    Neuropsychopharmacology Research Group, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
    Drugs Aging 29:167-79. 2012
    ..Given the importance of caregiver burden and its negative consequences for the caregiver and the patient, future clinical trials should pay more attention to this crucial outcome...
  26. ncbi request reprint The relation between disease severity and cost of caring for patients with Alzheimer disease in Canada
    Nathan Herrmann
    Medical Outcomes and Research in Economics MORE Group, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
    Can J Psychiatry 55:768-75. 2010
    ..to characterize the cost of caring for an outpatient in Canada with Alzheimer disease (AD) based on disease severity, and to describe how costs change with increases in disease severity...
  27. ncbi request reprint Central serotonergic activity is related to the aggressive behaviors of Alzheimer's disease
    Krista L Lanctot
    Psychopharmacology Research Program and Department of Psychiatry, Sunnybrook and Women s College Health Sciences Centre, Toronto, Ontario, Canada
    Neuropsychopharmacology 27:646-54. 2002
    ..These results suggest a complex link between aggression in AD and central serotonergic dysfunction having interactions with gender and cognitive impairment...
  28. doi request reprint Changes in nursing burden following memantine for agitation and aggression in long-term care residents with moderate to severe Alzheimer's disease: an open-label pilot study
    Nathan Herrmann
    Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
    CNS Drugs 25:425-33. 2011
    ..Agitation and aggression are common neuropsychiatric symptoms of Alzheimer's disease (AD) with a negative impact on caregivers...
  29. doi request reprint Factor analysis of the Rivermead Post-Concussion Symptoms Questionnaire in mild-to-moderate traumatic brain injury patients
    Nathan Herrmann
    Sunnybrook Health Sciences Centre, 2075 Bayview Ave, Toronto, Ontario, M4N 3M5, Canada
    J Neuropsychiatry Clin Neurosci 21:181-8. 2009
    ..These results suggest that depression post-TBI may influence patient perception of postconcussion symptoms...
  30. ncbi request reprint Do atypical antipsychotics cause stroke?
    Nathan Herrmann
    Division of Geriatric Psychiatry, University of Toronto, Toronto, Ontario, Canada
    CNS Drugs 19:91-103. 2005
    ..At the present time, this association is another factor that clinicians should consider when weighing the risks and benefits of treating behavioural and psychological disturbances in elderly dementia patients...
  31. ncbi request reprint The contribution of neuropsychiatric symptoms to the cost of dementia care
    Nathan Herrmann
    Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
    Int J Geriatr Psychiatry 21:972-6. 2006
    ..To estimate the contribution of behavioral and psychological symptoms of dementia (BPSD) to the costs of care...
  32. doi request reprint Risk factors and viruses associated with hospitalization due to lower respiratory tract infections in Canadian Inuit children : a case-control study
    Anna Banerji
    Department of Pediatrics and Dalla Lana School of Public Health, St Michael s Hospital, University of Toronto, Toronto, Ontario, Canada
    Pediatr Infect Dis J 28:697-701. 2009
    ..To examine risk factors for lower respiratory tract infections (LRTI) hospital admission in the Canadian Arctic...
  33. pmc Higher cortisol predicts less improvement in verbal memory performance after cardiac rehabilitation in patients with coronary artery disease
    Mahwesh Saleem
    Neuropsychopharmacology Research Group, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, ON, Canada M4N 3M5 Department of Pharmacology and Toxicology, University of Toronto, 1 King s College Circle, Toronto, ON, Canada M5S 1A8
    Cardiovasc Psychiatry Neurol 2013:340342. 2013
    ..12), maximal oxygen uptake (F(1,50) = 1.88, P = 0.18), and body mass index (F(1,50) = 3.25, P = 0.08). Conclusion. Prolonged hypothalamic pituitary adrenal axis activation may interfere with exercise-related improvements in memory in CAD...
  34. doi request reprint Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analyses
    Mark Sinyor
    Department of Psychiatry, University of Toronto, Ontario, Canada
    J Clin Psychiatry 71:270-9. 2010
    ..To determine if the inclusion of a placebo arm and/or the number of active comparators in antidepressant trials influences the response rates of the active medication and/or placebo...
  35. ncbi request reprint Efficacy and tolerability of antidepressants for treatment of depression in coronary artery disease: a meta-analysis
    Yekta Dowlati
    Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario
    Can J Psychiatry 55:91-9. 2010
    ..Our objective was to quantitatively summarize the data on the efficacy and tolerability of antidepressant (AD) treatment for depression in CAD...
  36. ncbi request reprint Growth hormone response to clonidine predicts aggression in Alzheimer's disease
    Nathan Herrmann
    Department of Psychiatry, Sunnybrook and Women s College Health Sciences Centre, Room FG05, 2075 Bayview Avenue, Toronto, Ontario, Canada M4N 3M5
    Psychoneuroendocrinology 29:1192-7. 2004
    ..The neurobiology of aggression in Alzheimer's Disease (AD) remains unknown. The objective of this study was to determine if altered central noradrenergic (NE) responsiveness is related to aggression in AD...
  37. doi request reprint Discontinuing cholinesterase inhibitors: results of a survey of Canadian dementia experts
    Nathan Herrmann
    Department of Psychiatry and Faculty of Medicine, University of Toronto, and Division of Geriatric Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
    Int Psychogeriatr 23:539-45. 2011
    ..Because there is little data to help clinicians to decide on when it is safe and appropriate to discontinue ChEIs after long-term use, practices may vary widely...
  38. ncbi request reprint Pharmacologic management of neuropsychiatric symptoms of Alzheimer disease
    Nathan Herrmann
    Department of Psychiatry, University of Toronto, Ontario
    Can J Psychiatry 52:630-46. 2007
    ..To systematically review published clinical trials of the pharmacotherapy of neuropsychiatric symptoms of Alzheimer disease (AD)...
  39. ncbi request reprint Behavioral correlates of GABAergic disruption in Alzheimer's disease
    Krista L Lanctot
    Neuropharmacology Research Program, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
    Int Psychogeriatr 19:151-8. 2007
    ..Our objective was to assess the relationship between plasma GABA (pGABA) levels and specific BPSD in patients with severe AD...
  40. ncbi request reprint Strategic subcortical hyperintensities in cholinergic pathways and executive function decline in treated Alzheimer patients
    Pearl Behl
    Division of Neurology, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, 160 Russell Jarvis Drive, Toronto, Ontario, Canada
    Arch Neurol 64:266-72. 2007
    ....
  41. ncbi request reprint Zinc in depression: a meta-analysis
    Walter Swardfager
    Neuropsychopharmacology Research Group, Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, Canada Toronto Rehabilitation Institute, University of Toronto, Toronto, Ontario, Canada Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada
    Biol Psychiatry 74:872-8. 2013
    ..This study sought to quantitatively summarize the clinical data comparing peripheral blood zinc concentrations between depressed and nondepressed subjects...
  42. ncbi request reprint Platelet activating factors in depression and coronary artery disease: a potential biomarker related to inflammatory mechanisms and neurodegeneration
    Graham Mazereeuw
    Sunnybrook Research Institute, Toronto, Ontario, Canada Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada Neural Regeneration Laboratory, Ottawa Institute of Systems Biology, Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada CIHR Training Program in Neurodegenerative Lipidomics, Canada
    Neurosci Biobehav Rev 37:1611-21. 2013
    ..In summary, PAFs are implicated in leading mechanisms associated with depression in CAD. PAFs may therefore be associated with the persistence of depression in CAD and related to neurodegenerative and cognitive sequelae. ..
  43. doi request reprint Effects of ω-3 fatty acids on cognitive performance: a meta-analysis
    Graham Mazereeuw
    Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
    Neurobiol Aging 33:1482.e17-29. 2012
    ..This meta-analysis examined the neuropsychological benefit of n-3 FAs in randomized double-blind placebo-controlled studies (RCTs) including healthy, CIND, or AD subjects...
  44. doi request reprint The role of dopamine in symptoms and treatment of apathy in Alzheimer's disease
    Robert A Mitchell
    Neuropsychopharmacology, Sunnybrook Health Sciences Centre, Toronto, Canada
    CNS Neurosci Ther 17:411-27. 2011
    ..The DAergic system is closely related to the brain reward system (BRS) and some studies have suggested that dysfunction in the DAergic system may account for symptoms of apathy in the AD population...
  45. doi request reprint Exercise intervention and inflammatory markers in coronary artery disease: a meta-analysis
    Walter Swardfager
    Sunnybrook Research Institute, Toronto, Ontario, Canada
    Am Heart J 163:666-76.e1-3. 2012
    ..We performed a meta-analysis of changes in inflammatory biomarkers over the course of exercise interventions in patients with CAD...
  46. ncbi request reprint A SPECT study of apathy in Alzheimer's disease
    Krista L Lanctot
    Department of Psychiatry, University of Toronto, Toronto, Ont, Canada
    Dement Geriatr Cogn Disord 24:65-72. 2007
    ..To assess the association between regional cerebral blood flow (rCBF) and apathy in Alzheimer's Disease (AD)...
  47. ncbi request reprint A positron emission tomography study of 5-hydroxytryptamine-1A receptors in Alzheimer disease
    Krista L Lanctot
    Neuropharmacology Research Program and Geriatric Psychiatry, Toronto, Ontario, Canada
    Am J Geriatr Psychiatry 15:888-98. 2007
    ..Postmortem studies suggest decreased 5-HT(1A) receptors in patients with Alzheimer disease (AD), but this has not been confirmed in vivo. Our primary objective was to assess the extent of 5-HT(1A) receptor losses in mild to moderate AD...
  48. doi request reprint The cost effectiveness of palivizumab in term Inuit infants in the Eastern Canadian Arctic
    Derrick Y Tam
    Medical Outcomes and Research in Economics Group, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, Ontario, Canada
    J Med Econ 12:361-70. 2009
    ..Canadian, Inuit, full term infants have the highest rate of respiratory syncytial virus (RSV) infection globally, which results in substantial costs associated hospitalisation...
  49. ncbi request reprint The role of norepinephrine in the behavioral and psychological symptoms of dementia
    Nathan Herrmann
    Division of Geriatric Psychiatry, Sunnybrook and Women s College Health Sciences Centre, Toronto, ON M4N 3M5, Canada
    J Neuropsychiatry Clin Neurosci 16:261-76. 2004
    ..With greater appreciation of the underlying neurobiology of behavioral and psychological symptoms of dementia (BPSD) more effective, rational, targeted pharmacotherapy will hopefully emerge...
  50. ncbi request reprint Indoleamine 2,3-dioxygenase activation and depressive symptoms in patients with coronary artery disease
    Walter Swardfager
    Neuropsychopharmacology Research Group, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
    Psychoneuroendocrinology 34:1560-6. 2009
    ..non-depressed patients (45.6+/-20.0 micromol/mmol vs. 38.5+/-15.7 micromol/mmol, F=3.778, p=.055) when controlling for age, sex and tACS. Activation of IDO is associated with the severity of depressive symptoms among patients with CAD...
  51. ncbi request reprint Respiratory syncytial virus prophylaxis in down syndrome: a prospective cohort study
    Hao Yi
    Medical Outcomes and Research in Economics Research Group, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
    Pediatrics 133:1031-7. 2014
    ..We compared hospitalization rates due to respiratory tract infection in children with DS aged <2 years who prospectively received palivizumab during the RSV season with a previously published, similar untreated DS birth cohort...
  52. pmc Ceramides predict verbal memory performance in coronary artery disease patients undertaking exercise: a prospective cohort pilot study
    Mahwesh Saleem
    Neuropsychopharmacology Research Group, Sunnybrook Health Sciences Centre, Toronto, Ontario M4N 3M5, Canada
    BMC Geriatr 13:135. 2013
    ..In this study, concentrations of very long chain ceramides (C22:0 and C24:0) were assessed as predictors of changes in verbal memory performance over 1 year in subjects with CAD undertaking cardiac rehabilitation (CR)...
  53. doi request reprint A review of cost-effectiveness of palivizumab for respiratory syncytial virus
    Julia M Hussman
    Medical Outcomes and Research in Economics Research Group, Sunnybrook Research Institute, Toronto, ON, Canada
    Expert Rev Pharmacoecon Outcomes Res 12:553-67. 2012
    ..Overall, cost-effectiveness results were inconsistent. Some studies reported favorable outcomes, while others did not, or were inconclusive. Factors to consider in the interpretation of such economic evaluations are discussed...
  54. doi request reprint Revisiting the cholinergic hypothesis of behavioral and psychological symptoms in dementia of the Alzheimer's type
    Tanya Pinto
    Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
    Ageing Res Rev 10:404-12. 2011
    ..Biochemical and neuroimaging studies of BPSD in Alzheimer's patients support these pharmacological data. This review discusses the literature describing the association between cholinergic deficiency and manifestations of BPSD...
  55. doi request reprint Sponsorship, antidepressant dose, and outcome in major depressive disorder: meta-analysis of randomized controlled trials
    Mark Sinyor
    Department of Psychiatry, University of Toronto, Toronto, Canada
    J Clin Psychiatry 73:e277-87. 2012
    ..This study aims to determine the relationship between sponsorship and antidepressant dosing and efficacy in randomized controlled trials for major depressive disorder...
  56. doi request reprint The cost effectiveness of palivizumab: a systematic review of the evidence
    Kelly A Smart
    Medical Outcomes and Research in Economics MORE, Sunnybrook Health Sciences Centre and Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada
    J Med Econ 13:453-63. 2010
    ..The objective was to systematically examine the cost effectiveness of palivizumab in defined infant groups and identify important cost and outcome determinants...
  57. doi request reprint A meta-analysis of cytokines in major depression
    Yekta Dowlati
    Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada
    Biol Psychiatry 67:446-57. 2010
    ..Our objective was to quantitatively summarize the data on concentrations of specific cytokines in patients diagnosed with a major depressive episode and controls...
  58. doi request reprint Current and emerging drug treatment options for Alzheimer's disease: a systematic review
    Nathan Herrmann
    Neuropsychopharmacology Research Program, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
    Drugs 71:2031-65. 2011
    ..This systematic review critically examines the efficacy and safety data for currently approved drugs and emerging treatments in AD, as well as discussing the present and future directions of innovation in this field...
  59. doi request reprint Sub-threshold cognitive impairment in multiple sclerosis: the association with cognitive reserve
    Anthony Feinstein
    Department of Psychiatry, Sunnybrook Health Sciences Centre, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada
    J Neurol 260:2256-61. 2013
    ..The high premorbid IQ in this group does not prevent, but 'softens' the impact of cognitive decline. These findings provide novel evidence supporting cognitive reserve as a protective factor in relation to cognitive dysfunction in MS...
  60. doi request reprint Potential roles of zinc in the pathophysiology and treatment of major depressive disorder
    Walter Swardfager
    Neuropharmacology Research Group, Sunnybrook Research Institute, Toronto, ON, Canada
    Neurosci Biobehav Rev 37:911-29. 2013
    ..Initial randomized trials suggest a benefit of zinc supplementation. In summary, molecular and animal behavioral data support the clinical significance of zinc in the setting of MDD...
  61. ncbi request reprint Antidepressant use during pregnancy and the rates of spontaneous abortions: a meta-analysis
    Michiel E H Hemels
    Department of Pharmacology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
    Ann Pharmacother 39:803-9. 2005
    ....
  62. pmc Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits
    Jennifer Glass
    University of Toronto, Department of Pharmaceutical Sciences, Toronto, ON, Canada M5S 2S2
    BMJ 331:1169. 2005
    ..To quantify and compare potential benefits (subjective reports of sleep variables) and risks (adverse events and morning-after psychomotor impairment) of short term treatment with sedative hypnotics in older people with insomnia...
  63. pmc Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer's disease
    Krista L Lanctot
    Neuropsychopharmacology Research Program and HOPE Research Centre, Sunnybrook and Women s College Health Sciences Centre, Toronto, Ont
    J Psychiatry Neurosci 28:13-26. 2003
    ..Studying correlates of response may help to elucidate the mechanism of action of acetylcholinesterase inhibitors...
  64. doi request reprint The serotonin transporter polymorphisms and major depression following traumatic brain injury
    Florance Chan
    Sunnybrook Health Sciences Centre, Toronto, ON, Canada
    Brain Inj 22:471-9. 2008
    ..The purpose of this study was to examine the role of the serotonin transporter gene polymorphisms on the risk of major depression following traumatic brain injury (TBI)...
  65. ncbi request reprint Adverse drug events in cognitively impaired elderly patients
    Hooman Ganjavi
    Neuropharmacology Research, Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
    Dement Geriatr Cogn Disord 23:395-400. 2007
    ..Adverse drug events (ADEs) are a frequent problem encountered in the elderly. The aim of this study was to elucidate the factors that influence ADEs in an elderly population with cognitive impairment...
  66. ncbi request reprint Benzodiazepine use and driving: a meta-analysis
    Mark J Rapoport
    Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
    J Clin Psychiatry 70:663-73. 2009
    ..The purpose of the present study was to examine the experimental and epidemiologic evidence linking benzodiazepine use to driving impairment...
  67. doi request reprint The pharmacoeconomics of cognitive enhancers in moderate to severe Alzheimer's disease
    Jaclyn Cappell
    Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
    CNS Drugs 24:909-27. 2010
    ....
  68. ncbi request reprint Atypical antipsychotics and risk of cerebrovascular accidents
    Nathan Herrmann
    Institute for Clinical and Evaluative Sciences, University of Toronto, Toronto, Ontario, Canada
    Am J Psychiatry 161:1113-5. 2004
    ..This study examined the association between atypical antipsychotic use and stroke in the elderly...
  69. ncbi request reprint Atypical antipsychotics for neuropsychiatric symptoms of dementia: malignant or maligned?
    Nathan Herrmann
    Department of Psychiatry, University of Toronto, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
    Drug Saf 29:833-43. 2006
    ....
  70. ncbi request reprint Relationship between cardiopulmonary fitness and depressive symptoms in cardiac rehabilitation patients with coronary artery disease
    Walter Swardfager
    Department of Pharmacology, University of Toronto, Toronto, Canada
    J Rehabil Med 40:213-8. 2008
    ..To identify independent predictors of depressive symptoms in a cohort of patients with coronary artery disease entering cardiac rehabilitation...
  71. ncbi request reprint Gender, aggression and serotonergic function are associated with response to sertraline for behavioral disturbances in Alzheimer's disease
    Krista L Lanctot
    Psychopharmacology Research Program and Geriatric Psychiatry, Sunnybrook and Women s College Health Sciences Centre, University of Toronto, 207s Bayview Avenue, Toronto, Ontario M4N 3M5, Canada
    Int J Geriatr Psychiatry 17:531-41. 2002
    ..Indications for serotonergic medications in the treatment of behavioral disorders associated with Alzheimer's disease (AD) remain to be established...
  72. doi request reprint Changing costs and the impact on RSV prophylaxis
    Kelly A Smart
    Medical Outcomes and Research in Economics Group, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
    J Med Econ 13:705-8. 2010
    ....
  73. doi request reprint Interleukin-17 in post-stroke neurodegeneration
    Walter Swardfager
    Neuropsychopharmacology Research Group, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario M4N 3M5, Canada
    Neurosci Biobehav Rev 37:436-47. 2013
    ....
  74. pmc Therapy for Alzheimer's Disease: How Effective are Current Treatments?
    Krista L Lanctot
    Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
    Ther Adv Neurol Disord 2:163-80. 2009
    ..This has spurred the development of new disease-modifying therapies that aim to have a greater impact on this debilitating illness...
  75. doi request reprint Pediatric cancer rates after universal folic acid flour fortification in Ontario
    Sandy G Grupp
    Institute of Medical Science, University of Toronto, Hospital for Sick Children, Toronto, Canada
    J Clin Pharmacol 51:60-5. 2011
    ..This corroborates a recent case-control study from Germany. These data may also provide some reassurance that universal flour fortification does not heighten the risk of pediatric cancer...